Evogene Ltd. CPO Nir Arbel to Step Down
Ticker: EVGN · Form: 6-K · Filed: Jun 20, 2024 · CIK: 1574565
Sentiment: neutral
Topics: management-change, personnel
TL;DR
Evogene's CPO is out August 15th due to a move, search for replacement underway.
AI Summary
Evogene Ltd. announced that Nir Arbel, the Chief Product Officer, will step down from his position on August 15, 2024, due to relocation. The company is currently searching for a replacement and expressed gratitude for Mr. Arbel's contributions.
Why It Matters
A change in key management personnel can impact a company's strategic direction and operational execution, potentially affecting investor confidence.
Risk Assessment
Risk Level: low — This filing reports a standard management change and does not indicate any significant financial or operational distress.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- Nir Arbel (person) — Chief Product Officer
FAQ
When will Nir Arbel officially step down as Chief Product Officer?
Mr. Arbel will remain in office through August 15, 2024.
What is the reason for Nir Arbel's departure?
Mr. Arbel is stepping down due to relocation.
Is Evogene Ltd. actively searching for a replacement CPO?
Yes, a search for a replacement is being conducted.
What is Evogene Ltd.'s primary business sector?
Evogene Ltd. is in the AGRICULTURE CHEMICALS sector, SIC code 2870.
What form is Evogene Ltd. filing?
Evogene Ltd. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
Filing Stats: 259 words · 1 min read · ~1 pages · Grade level 9.5 · Accepted 2024-06-20 16:05:09
Filing Documents
- zk2431596.htm (6-K) — 7KB
- 0001178913-24-002015.txt ( ) — 8KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Evogene Ltd., or Evogene, reports changes in the management: Mr. Nir Arbel, the Company's Chief Product Officer, requested to step down from his position as CPO, due to relocation. Mr. Arbel will remain in office through August 15, 2024, while a search for a replacement is being conducted. Evogene thanks Mr. Arbel for his services. This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statements on Form F-3 (File No. 333-277565) and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 20, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer